This is a continuation of the round table format, discussing real life case management with my colleagues who are lung cancer experts at other institutions, This case is the second half of discussion centered around a never-smoking Asian woman who doesn’t have an EGFR mutation, and specifically the decision-making process of what first line chemotherapy-based treatment to recommend and whether to continue with maintenance therapy. My guests for the discussion are Drs. Janessa Laskin, medical oncologist from British Columbia Cancer Agency in Vancouver, BC, and Alan Sandler, medical oncologist and Director of Hematology/Oncology at Oregon Health & Science University in Portland.
Here is the video version, audio, transcript, and associated figures.
rt-laskin-sandler-never-smoker-egfr-wt-1st-line-chemo-and-maint-rx-audio-podcast
rt-laskin-sandler-never-smoker-egfr-wt-1st-line-chemo-and-maint-rx-transcript
rt-laskin-sandler-never-smoker-egfr-wt-1st-line-chemo-and-maint-rx-figures
I’ll have another case from the same round table with Drs. Laskin and Sandler soon. In the meantime, we are happy to review your own cases and questions if you would like to submit them and have questions that are timely and potentially relevant to a broad audience in the cancer community. So if you’re interested, please e-mail a brief synopsis and perhaps your central question(s) to west@cancergrace.org for consideration.
Podcast: Play in new window | Download
Related posts:
Posted on January 17, 2010 at 5:14 am
This area of non-smoking and Asian patients,EFGR mutations and the use of Iressa and Tarceva is another one where Cancergrace appears to be doing significant original work which could be pulled together to be highlighted on the site.Faculty seem to have an ongoing interest and there also seem to be a growing number of new questions (but on subjects already covered ) on the forums, so a clear display of work already done may cut down future repetitive answers.